SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cambridge Antibody Technology Group
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jongmans who started this subject1/2/2003 6:30:03 AM
From: nigel bates  Read Replies (1) of 625
 
Are Abbott and CAT going to have anything left out of D2E7 after everyone has had their cut ?? <g>

SYDNEY (Dow Jones)--Australian biotechnology group Peptech Ltd. said Thursday that U.S. pharmaceutical company Abbott Industries Inc. received U.S. Food & Drug Administration approval to market Humira earlier than expected.
Peptech has a royalty agreement with Abbott Laboratories in relation to that company's rheumatoid arthritis drug Humira, previously known as D2E7...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News